List of publication about nSMOL technology:

Analyst, 2014, 139, 576

Selective detection of complementarity determining regions of monoclonal antibody by limiting protease access to the substrate: nanosurface and molecular-orientation limited proteolysis†

Noriko Iwamoto,^‡a Takashi Shimada,^‡*aYukari Umino,^a Chikage Aoki,^a Yutaka Aoki,^a

Taka-Aki Sato,^a Akinobu Hamada^b and Hitoshi Nakagama^c

^aLifeScience Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan. E-mail: t-shima@shimadzu.co.jp; Fax: +81-3-3547-7636

^bDepartment of Clinical Pharmacology, Group for Translational Research Support Core, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

^cDivision of Integrative Omics and Bioinformatics, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

^† Electronic supplementary information (ESI) available: Experimental details, the effect of antibody fragmentation by nSMOL proteolysis, the effect of Fab-selective nSMOL proteolysis against solution digestion, product ion spectra of Trastuzumab peptides, calibration curves of Trastuzumab in plasma, detected peptide lists of Trastuzumab and Bevacizumab, and optimized MRM conditions. See DOI: 10.1039/c3an02104a

Anal. Methods, 2015,7, 9177-9183

The development of the validated LCMS bioanalysis of trastuzumab in human plasma using a selective detection method for complementarity determining regions of monoclonal antibodies: nano-surface and molecular-orientation limited (nSMOL) proteolysis†

Noriko Iwamoto,^a Naoe Yamane,^b Yukari Umino,^a Akinobu Hamada^c and Takashi Shimada^*a

^aLife Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan. E-mail: t-shima@shimadzu.co.jp; Fax: +81-3-3547-7636; Tel: +81-3-3547-7635

^bJCL Bioassay Corporation, Miyahara, Yodogawa-ku, Osaka 532-0003, Japan

^cDivision of Clinical Pharmacology and Translational Research, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ay01588j

Bioanalysis (2016) 8(10), 1009–1020

Application of nano-surface and molecular-orientation limited proteolysis to LC–MS bioanalysis of cetuximab

Noriko Iwamoto¹, Megumi Takanashi¹, Yukari Umino¹, Chikage Aoki¹, Akinobu Hamada² & Takashi Shimada^*,1

¹Life Science Research Center, SHIMADZU Corporation, Kanda-Nishikicho, Chiyoda-ku, Tokyo 101-8448, Japan

²Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan

*Author for correspondence:

Tel.: +81 3 3547 7635

Fax: +81 3 3547 7636

t-shima@shimadzu.co.jp

Biol. Pharm. Bull. 39, 1187–1194 (2016)

Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nanosurface and Molecular-Orientation Limited (nSMOL) Proteolysis

Noriko Iwamoto,^aMegumi Takanashi,^aAkinobu Hamada,^band Takashi Shimada^*,a

^aLife Science Research Center, Shimadzu Corporation; Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101–8448, Japan: and

^bDivision of Clinical Pharmacology, National Cancer Center; Tsukiji, Chuo-ku, Tokyo 104–0045, Japan.

* To whom correspondence should be addressed. e-mail: t-shima@shimadzu.co.jp

Iwamoto et al., Clin Pharmacol Biopharm 2016, 5:4

Multiplex LCMS Bioanalysis of Brentuximab Vedotin, Rituximab and Cetuximab towards Therapeutic Drug Monitoring Application by Combined Calibration Curve Using Fab-Selective Limited Proteolysis nSMOL

Noriko Iwamoto¹, Megumi Takanashi¹, Akinobu Hamada² and Takashi Shimada^1*

¹Technology Research Laboratory, SHIMADZU Corporation, Tokyo, Japan

²Division of Molecular Pharmacology & Pharmacokinetics, National Cancer Center Research Institute, Tokyo, Japan

Drug Metabolism and Pharmacokinetics 31 (2016) 46e50

Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis

Noriko Iwamoto ^a, Yukari Umino ^a, Chikage Aoki ^a, Naoe Yamane ^b, Akinobu Hamada ^c,

Takashi Shimada ^a^,^*

^aLife Science Research Center, SHIMADZU Corporation, Kanda-Nishiki-cho, Chiyoda-ku, Tokyo 101-8448, Japan

^bCMIC Pharma Science Co., Ltd., Shibaura, Minato-ku, Tokyo 105-0023, Japan

^cDivision of Clinical Pharmacology, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Journal of Chromatography B, 1023 (2016) 9–16

Validated LC–MS/MS analysis of immune checkpoint inhibitorNivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis

Noriko Iwamotoa,¹, Takashi Shimadaa,¹, Hiroyuki Terakado^b, Akinobu Hamada^c,^∗

^aLife Science Research Center, SHIMADZU Corporation, Japan

^bDepartment of Pharmacy, National Cancer Center Hospital, Japan

^cDivision of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan